US · CRNX · BIOTECHNOLOGY
Crinetics Pharmaceuticals, Inc. (CRNX) intrinsic value and stock valuation
$84.95as of 2026-11-21 · Mkt cap 8.91B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Crinetics Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values CRNX with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from CRNX’s statements →
Crinetics Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Praxis Precision Medicines, Inc. (PRAX) $300.43
- Kymera Therapeutics, Inc. (KYMR) $115.31
- Immunovant, Inc. (IMVT) $31.77
- Xenon Pharmaceuticals Inc. (XENE) $37.04
- ACADIA Pharmaceuticals Inc. (ACAD) $17.11
- Dyne Therapeutics, Inc. (DYN) $15.50
- Viking Therapeutics, Inc. (VKTX) $24.77
- NewAmsterdam Pharma Company N.V. (NAMS) $18.41
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.7M | $1.04M | $4.01M | $4.74M | $1.08M |
| Operating income | -$-516.77M | -$-338.85M | -$-222.61M | -$-167.88M | -$-107.7M |
| Net income | -$-465.32M | -$-298.41M | -$-214.53M | -$-163.92M | -$-107.64M |
| EPSd | -$-4.95M | -$-3.69M | -$-3.69M | -$-3.15M | -$-2.8M |
| Operating cash flow | -$-377.92M | -$-225.97M | -$-166.31M | -$-115.2M | -$-88.59M |
| Capital expenditure | -$-5.76M | -$-3.84M | -$-4.69M | -$-1.66M | -$-440K |
| Free cash flow | -$-383.68M | -$-229.81M | -$-171M | -$-116.86M | -$-89.02M |
| Total assets | $1.14B | $1.43B | $635.4M | $352.2M | $351M |
| Total debt | $48.5M | $51.7M | $51.7M | $3.08M | $4.01M |
| Net debt | -$-52.99M | -$-212.82M | -$-3.17M | -$-29.6M | -$-196.68M |
| Total equity | $992.1M | $1.32B | $539.1M | $316.3M | $331.9M |
| Cash and short-term investments | $1.03B | $1.35B | $558.6M | $334.4M | $333.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.7M | $1.04M | $4.01M | $4.74M | $1.08M |
| Cost of revenue | $1.08M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $6.62M | $1.04M | $4.01M | $4.74M | $1.08M |
| Research and development expenses | $332.1M | $240.2M | $168.5M | $130.2M | $84.3M |
| Selling, general and administrative expenses | $191.3M | $99.7M | $58.1M | $42.4M | $24.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $523.4M | $339.9M | $226.6M | $172.6M | $108.8M |
| Cost and expenses | $524.5M | $339.9M | $226.6M | $172.6M | $108.8M |
| Interest income | $52M | $41.4M | $13.4M | $4.32M | $160K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $3.89M | $2.79M | $1.1M | $980K | $920K |
| Ebitda | -$-461.25M | -$-295.62M | -$-213.43M | -$-162.94M | -$-106.72M |
| Operating income | -$-516.77M | -$-338.85M | -$-222.61M | -$-167.88M | -$-107.7M |
| Total other income/expenses, net | $51.6M | $40.5M | $8.08M | $3.96M | $60K |
| Income before tax | -$-465.14M | -$-298.41M | -$-214.53M | -$-163.92M | -$-107.64M |
| Income tax expense | $180K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-465.32M | -$-298.41M | -$-214.53M | -$-163.92M | -$-107.64M |
| Weighted average shares outstanding | $94.1M | $80.8M | $58.1M | $52M | $38.4M |
| Weighted average diluted shares outstanding | $94.1M | $80.8M | $58.1M | $52M | $38.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.03B | $1.35B | $558.6M | $334.4M | $333.7M |
| Net receivables | $590K | $8.47M | $9.35M | $2.42M | $2.03M |
| Inventory | $2.02M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $1.05B | $1.38B | $574.2M | $345.2M | $344.7M |
| Property, plant and equipment, net | $54.8M | $55.6M | $57.4M | $4.99M | $4.72M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $800K | $800K | $1.77M | $1.97M | $1.01M |
| Total non-current assets | $87.2M | $59.2M | $61.2M | $6.99M | $6.29M |
| Total assets | $1.14B | $1.43B | $635.4M | $352.2M | $351M |
| Accounts payable | $22.6M | $5.85M | $6.55M | $6.88M | $4.27M |
| Short-term debt | $6.49M | $7.15M | $4.17M | $1.05M | $940K |
| Deferred revenue | $1.24M | $2.18M | $2.06M | $2.24M | $0.00 |
| Total current liabilities | $85.1M | $59.7M | $43.9M | $27.7M | $16M |
| Long-term debt | $42.1M | $44.6M | $47.6M | $2.02M | $3.07M |
| Deferred revenue, non-current | $3.81M | $4.7M | $4.75M | $6.1M | $0.00 |
| Total non-current liabilities | $58.3M | $50.1M | $52.3M | $8.12M | $3.08M |
| Capital lease obligations | $42.1M | $51.7M | $47.6M | $2.02M | $3.07M |
| Total liabilities | $143.4M | $109.8M | $96.3M | $35.9M | $19.1M |
| Common stock | $2.41B | $2.28B | $1.19B | $759.4M | $607.6M |
| Retained earnings | -$-1.42B | -$-952.11M | -$-653.7M | -$-439.17M | -$-275.25M |
| Accumulated other comprehensive income (loss) | $1.75M | $960K | $980K | -$-3.93M | -$-380K |
| Total equity | $992.1M | $1.32B | $539.1M | $316.3M | $331.9M |
| Total investments | $926.4M | $1.09B | $505.4M | $303.7M | $134M |
| Total debt | $48.5M | $51.7M | $51.7M | $3.08M | $4.01M |
| Net debt | -$-52.99M | -$-212.82M | -$-3.17M | -$-29.6M | -$-196.68M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-465.32M | -$-298.41M | -$-214.53M | -$-163.92M | -$-107.64M |
| Depreciation and amortization | $3.89M | $2.79M | $1.1M | $980K | $920K |
| Stock-based compensation | $91M | $69.4M | $40.9M | $28.3M | $17.4M |
| Change in working capital | $4.84M | $11.6M | $8.04M | $18.6M | $1.1M |
| Accounts receivable | -$-590K | $17.5M | $14.7M | $11M | $6.29M |
| Inventory | -$-2.02M | $0.00 | $0.00 | $0.00 | -$-6.29M |
| Accounts payable | $29M | $0.00 | $0.00 | $0.00 | $6.29M |
| Net cash provided by operating activities | -$-377.92M | -$-225.97M | -$-166.31M | -$-115.2M | -$-88.59M |
| Investments in property, plant and equipment | -$-5.76M | -$-3.84M | -$-4.69M | -$-1.66M | -$-440K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $420K |
| Net cash used for investing activities | $173.9M | -$-574.82M | -$-200.41M | -$-173.98M | -$-56.48M |
| Common stock issued | $40.6M | $970.1M | $369M | $117.2M | $249.5M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $40.6M | $1.01B | $388.9M | $122M | $252.7M |
| Net change in cash | -$-163.51M | $209.7M | $22.2M | -$-167.22M | $107.6M |
| Cash at end of period | $102.3M | $265.9M | $56.2M | $34M | $201.2M |
| Operating cash flow | -$-377.92M | -$-225.97M | -$-166.31M | -$-115.2M | -$-88.59M |
| Capital expenditure | -$-5.76M | -$-3.84M | -$-4.69M | -$-1.66M | -$-440K |
| Free cash flow | -$-383.68M | -$-229.81M | -$-171M | -$-116.86M | -$-89.02M |
Line items
Line items
Line items
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
- CEO
- R. Scott Struthers
- Employees
- 594
- Beta
- 0.13
Explore
Frequently asked questions
What is the intrinsic value of Crinetics Pharmaceuticals, Inc. (CRNX)?
Crinetics Pharmaceuticals, Inc. (CRNX) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CRNX undervalued?
CRNX trades at a price of $84.95 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.